Study of Breast Cancer Organelle Features and Protein Expression in Early and Metastatic Breast Cancer Subtypes

What this Trial Is About

Researchers are studying participants with early breast cancer or de novo metastatic breast cancer to create a combined ESPRESSO phenotype and spatial proteomics data collection across four groups based on tumor subtypes. This prospective, open-label study aims to understand fatty acid accumulation in lipid droplets and explore other organelle features like lysosomal acidity and nuclear organization. The study will last nine years, with four years of recruitment and five years of participation for each individual. Participants will be assigned to one of four cohorts depending on their tumor subtype Triple Negative early breast cancer, HER2-positive early breast cancer, Luminal early breast cancer, or de novo metastatic breast cancer of any subtype. Biological samples such as fresh tumor biopsies, blood, ascitic fluid, or pleural fluid will be collected at multiple time points before, during, and after treatment as part of standard care or clinical trials. Tumor biopsies will be performed specifically for this study to provide fresh material needed for laboratory analysis using the ESPRESSO technique. During the study, data will be collected at baseline and throughout scheduled visits aligned with clinical care or trial assessments for up to five years. This includes tumor response and adverse events related to study procedures. Researchers will measure fatty acid levels in lipid droplets as the primary outcome and assess pathological response, event-free survival, and progression-free survival as secondary outcomes. Participants will be monitored regularly through blood samples and other biological specimen collection to support these evaluations.

Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers